FDA Approves Cosibelimab for Cutaneous SCC
The US Food and Drug Administration (FDA) has approved the immune checkpoint inhibitor cosibelimab (Unloxcyt; Checkpoint Therapeutics, Inc.) for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation. The programmed death ligand-1 (PD-L1)–blocking antibody is the first and only treatment
The US Food and Drug Administration (FDA) has approved the immune checkpoint inhibitor cosibelimab (Unloxcyt; Checkpoint Therapeutics, Inc.) for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation. The programmed death ligand-1 (PD-L1)–blocking antibody is the first and only treatment …
Read More
About Author
